Background: Mast cells (MC) and basophils are effector cells of allergic reactions. Growth and function of these cells are regulated by a network of cytokines, other ligands, and respective cell surface membrane receptors. Methods: In the present study, we examined the expression of novel CD antigens on human lung MC, skin MC, blood basophils, the MC line HMC-1, and the basophil cell line KU-812. Expression of surface antigens was analyzed by monoclonal antibodies (mAbs) and indirect immunofluorescence staining techniques. Results: Primary MC were found to react with mAbs against KIT (CD117), the signal regulatory protein SIRP-α (CD172a), and the ectoenzyme E-NPP3 (CD203c). Human basophils were found to express large amounts of E-NPP3 and lower levels of Siglec-5 (CD170), CXCR4 (CD184) and SIRP-α. The HMC-1 cell line was recognized by mAbs against SIRP-α, CXCR4, endothelial protein C receptor (CD201) and E-NPP3. KU-812 cells were found to react with mAbs against E-NPP3, CXCR4 and glycophorin C (CD236R), but did not react with mAb against endothelial protein C receptor. Most of the other CD antigens tested disclosed negative results. Conclusions: In summary, our data provide further evidence that MC and basophils express a unique composition of surface antigens. The use of novel CD antibodies may help to isolate MC and basophils and to study their functional properties.

1.
Schwartz LB: The mast cell; in Kaplan AP (ed): Allergy. Edinburgh, Churchill Livingstone, 1985, vol 1, pp 53–92.
2.
Valent P, Bettelheim P: The human basophil. Crit Rev Oncol Hematol 1990;10:327–352.
3.
Johnston SL, Holgate ST: Cellular and chemical mediators – their roles in allergic diseases. Curr Opin Immunol 1989;2:513–524.
4.
Serafin WE, Austen KF: Mediators of immediate hypersensitivity reactions. N Engl J Med 1987;317:30–34.
5.
Ishizaka T, Ishizaka K: Activation of mast cells for mediator release through IgE receptors. Prog Allergy 1984;34:188–235.
6.
Metzger H: The receptor with high affinity for IgE. Immunol Rev 1992;125:37–48.
7.
Sperr WR, Agis H, Czerwenka K, Klepetko W, Kubista E, Boltz-Nitulescu G, Lechner K, Valent P: Differential expression of cell surface integrins on human mast cells and basophils. Ann Hematol 1992;65:10–16.
8.
Wimazal F, Ghannadan M, Müller MR, End A, Willheim M, Meidlinger P, Schernthaner GH, Jordan JH, Hagen W, Sperr WR, Czerwenka K, Lechner K, Valent P: Expression of homing receptors and related molecules on human mast cells and basophils: A comparative analysis using multi-color flow cytometry and toluidine blue/immunofluorescence staining technique. Tissue Antigens 1999;54:499–507.
9.
Valent P, Majdic O, Maurer D, Bodger M, Muhm M, Bettelheim P: Further characterization of surface membrane structures expressed on human basophils and mast cells. Int Arch Allergy Appl Immunol 1990;91:198–203.
10.
Ghannadan M, Baghestanian M, Wimazal F, Eisenmenger M, Latal D, Kargül G, Walchshofer S, Sillaber C, Lechner K, Valent P: Phenotypic characterization of human skin mast cells by combined staining for toluidine blue and CD antibodies. J Invest Dermatol 1998;111:689–695.
11.
Agis H, Füreder W, Bankl HC, Kundi M, Sperr WR, Willheim M, Boltz-Nitulescu G, Butterfield JH, Kishi K, Lechner K, Valent P: Comparative phenotypic analysis of human mast cells, blood monocytes and blood basophils: Dissection of three distinct myeloid cell lineages. Immunology 1996;87:535–543.
12.
Valent P, Bettelheim P: Cell surface structures on human basophils and mast cells: Biochemical and functional characterization. Adv Immunol 1992;52:333–423.
13.
Füreder W, Agis H, Willheim M, Bankl HC, Maier U, Kishi K, Müller M, Czerwenka K, Radaszkiewicz T, Butterfield JH, Klappacher GW, Sperr WR, Oppermann M, Lechner K, Valent P: Differential expression of complement receptors on human mast cells and basophils: Evidence for mast cell heterogeneity and C5aR/CD88 expression on skin mast cells. J Immunol 1995;155:3152–3160.
14.
Valent P, Besemer J, Muhm M, Majdic O, Lechner K, Bettelheim P: Interleukin 3 activates human blood basophils via high-affinity binding sites. Proc Natl Acad Sci USA 1989;86:5542–5546.
15.
Valent P, Besemer J, Kishi K, di Padova F, Geissler K, Lechner K, Bettelheim P: Human basophils express interleukin-4 receptors. Blood 1990;76:1734–1738.
16.
Lopez AF, Lyons AB, Eglinton JM, Park LS, To LB, Clark SC, Vadas MA: Specific binding of human interleukin-3 and granulocyte-macrophage colony-stimulating factor to human basophils. J Allergy Clin Immunol 1990;85:99–102.
17.
Stockinger H, Valent P, Majdic O, Bettelheim P, Knapp W: Human blood basophils synthesize interleukin-2 binding sites. Blood 1990;75:1820–1826.
18.
Krieger M, Brunner T, Bischoff SC, von Tscharner V, Walz A, Moser B, Baggiolini M, Dahinden CA: Activation of human basophils through the IL-8 receptor. J Immunol 1992;149:2662–2667.
19.
Sillaber C, Strobl H, Bevec D, Ashman LK, Butterfield JH, Lechner K, Maurer D, Bettelheim P, Valent P: IL-4 regulates c-kit proto-oncogene product expression in human mast and myeloid progenitor cells. J Immunol 1991;147:4224–4228.
20.
Valent P, Schmidt G, Besemer J, Mayer P, Liehl E, Hinterberger W, Lechner K, Maurer D, Bettelheim P: Interleukin-3 is a differentiation factor for human basophils. Blood 1989;73:1763–1769.
21.
Bochner BS, Sterbinsky SA, Knol EF, Katz BJ, Lichtenstein LM, MacGlashan DW, Schleimer RP: Function and expression of adhesion molecules on human basophils. J Allergy Clin Immunol 1994;94:1157–1162.
22.
Lopez AF, Eglinton JM, Lyons AB, Tapley PM, To LB, Park LS, Clark SC, Vadas MA: Human interleukin-3 inhibits the binding of granulocyte-macrophage colony-stimulating factor and interleukin-5 to basophils and strongly enhances their functional properties. J Cell Physiol 1990;145:69–77.
23.
Valent P: The riddle of the mast cell: c-kit(CD117)-ligand as the missing link? Immunol Today 1994;15:111–114.
24.
Valent P, Besemer J, Sillaber C, Maurer D, Butterfield JH, Kishi K, Lechner K, Bettelheim P: Failure to detect interleukin-3 binding sites on human mast cells. J Immunol 1990;145:3432–3437.
25.
Schulman ES, MacGlashan DW, Peters SP, Schleimer RP, Newball HH, Lichtenstein LM: Human lung mast cells: Purification and characterization. J Immunol 1982;129:2662–2667.
26.
Valent P, Ashman LK, Hinterberger W, Eckersberger F, Majdic O, Lechner K, Maurer D, Bettelheim P: Mast cell typing: Demonstration of a distinct hemopoietic cell type and evidence for immunophenotypic relationship to mononuclear phagocytes. Blood 1989;73:1778–1785.
27.
Butterfield JH, Weiler D, Dewald G, Gleich GJ: Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk Res 1988;12:345–355.
28.
Kishi K: A new leukemia cell line with Philadelphia chromosome characterized as basophil precursors. Leuk Res 1985;9:381–390.
29.
Bühring HJ, Simmons PJ, Pudney M, Müller R, Jarrossay D, van Agthoven A, Willheim M, Brugger W, Valent P, Kanz L: The monoclonal antibody 97A6 defines a novel surface antigen expressed on human basophils and their multipotent and unipotent progenitors. Blood 1999;94:2343–2356.
30.
Kharitonenkov A, Chen Z, Sures I, Wang H, Schilling J, Ullrich A: A family of proteins that inhibit signalling through tyrosine kinase receptors. Nature 1997;386:181–186.
31.
Seiffert M, Cant C, Chen Z, Rappold I, Brugger W, Kanz L, Brown EJ, Ullrich A, Bühring HJ: Human signal-regulatory protein is expressed on normal, but not on subsets of leukemic myeloid cells and mediates cellular adhesion involving its counterreceptor CD47. Blood 1999;94:3633–3643.
32.
Timms JF, Carlberg K, Gu H, Chen H, Kamatkar S, Nadler MJS, Rohrschneider LR, Neel BG: Identification of major binding proteins and substrates for the SH2-containing protein tyrosine phosphatase SHP-1 in macrophages. Mol Cell Biol 1998;18:3838–3850.
33.
Kozlowski M, Larose L, Lee F, Le DM, Rottapel R, Siminovitch KA: SHP-1 binds and negatively modulates the c-Kit receptor by interaction with tyrosine 569 in the c-Kit juxtamembrane domain. Mol Cell Biol 1998;18:2089–2099.
34.
Piao X, Paulson R, van der Geer P, Pawson T, Bernstein A: Oncogenic mutation in the Kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1. Proc Natl Acad Sci USA 1996;93:14665–14669.
35.
Bühring HJ, Seiffert M, Giesert C, Marxer A, Kanz L, Valent P, Sano K: The basophil activation marker defined by antibody 97A6 is identical to the ectonucleotide pyrophosphatase/phosphodiesterase 3. Blood 2001;97:3303–3305.
36.
Bühring HJ, Valent P, Sano K: CD203c cluster report; in Mason DY, Simmons D, Clark E (eds): Leucocyte Typing VII. Oxford, Oxford University Press, in press.
37.
Cornish AL, Freeman S, Forbes G, Ni J, Zhang M, Cepeda M, Gentz R, Augustus M, Carter KC, Crocker PR: Characterization of siglec-5, a novel glycoprotein expressed on myeloid cells related to CD33. Blood 1998;92:2123–2132.
38.
Munday J, Floyd H, Crocker PR: Sialic acid binding receptors (siglecs) expressed by macrophages. J Leukoc Biol 1999;66:705–711.
39.
Oberlin E, Amara A, Bachelerie F, Bessia C, Virelizier JL, Arenzana-Seisdedos F, Schwartz O, Heard JM, Clark-Lewis I, Legler DF, Loetscher M, Baggiolini M, Moser B: The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature 1996;382:833–835.
40.
Bleul CC, Farzan M, Choe H, Parolin C, Clark-Lewis I, Sodroski J, Springer TA: The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 1996;382:829–833.
41.
Stain C, Stockinger H, Scharf M, Jäger U, Gössinger H, Lechner K, Bettelheim P: Human blood basophils display a unique phenotype including activation linked membrane structures. Blood 1987;70:1872–1879.
42.
Juremalm M, Hjertson M, Olsson N, Harvima I, Nilsson K, Nilsson G: The chemokine receptor CXCR4 is expressed within the mast cell lineage and its ligand stromal cell-derived factor-1alpha acts as a mast cell chemotaxin. Eur J Immunol 2000;30:3614–3622.
43.
Royer B, Varadaradjalou S, Saas P, Gabiot AC, Kantelip B, Feger F, Guillosson JJ, Kantelip JP, Arock M: Autocrine regulation of cord blood-derived human mast cell activation by IL-10. J Allergy Clin Immunol 2001;108:80–86.
44.
Nakazawa M, Mitjavila MT, Debili N, Casadevall N, Mayeux P, Rouyer-Fessard P, Dubart A, Romeo PH, Beuzard Y, Kishi K, et al: KU 812: A pluripotent human cell line with spontaneous erythroid terminal maturation. Blood 1989;73:2003–2013.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.